Two Sigma Ventures Leads Gameto $33M Series B to Support Women’s Health

Gunderson Dettmer represented client Two Sigma Ventures in leading the $33 million Series B financing of Gameto, a biotechnology company dedicated to advancing treatment options in women's health. Gameto brings together an experienced scientific management team with the vision and passion to develop a product suite to support women throughout their reproductive journeys.

In the U.S., the financing will support the clinical development of Fertilo, their lead investigational program that aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. In Australia and Latin America, the new capital will be used to support the commercial launches of Fertilo.

In the announcement of the transaction, Two Sigma Ventures partner Dusan Perovic said, "Gameto's pioneering approach to IVF has the potential to impact families and societies on a global scale. In addition to making treatments much easier and more accessible for women, Gameto's advanced IVF/egg-freezing solution addresses a massive societal need as we're living longer and looking to start families later in life while facing rising female and male infertility rates. By harnessing cutting-edge breakthroughs in genetic sequencing and cellular engineering – tools that didn't exist until recently – Gameto is poised to upend traditional IVF treatments to make them more accessible, convenient, and faster for anyone to start a family.

The Gunderson Dettmer deal team was led by Hozefa Botee and included Rafa Bellaver.

Two Sigma Ventures
Gameto